RU95116579A - PHARMACEUTICAL COMPOSITION (VARIANTS) AND A METHOD FOR PREVENTION OR TREATMENT (VARIANTS) COMPOSITION FOR PREVENTION OF RADIATION AND CHEMICAL, mammalian cells SYNTHETIC CATALYTIC radical scavengers USED AS ANTIOXIDANTS FOR PREVENTION AND TREATMENT OF DISEASES - Google Patents
PHARMACEUTICAL COMPOSITION (VARIANTS) AND A METHOD FOR PREVENTION OR TREATMENT (VARIANTS) COMPOSITION FOR PREVENTION OF RADIATION AND CHEMICAL, mammalian cells SYNTHETIC CATALYTIC radical scavengers USED AS ANTIOXIDANTS FOR PREVENTION AND TREATMENT OF DISEASESInfo
- Publication number
- RU95116579A RU95116579A RU95116579/14A RU95116579A RU95116579A RU 95116579 A RU95116579 A RU 95116579A RU 95116579/14 A RU95116579/14 A RU 95116579/14A RU 95116579 A RU95116579 A RU 95116579A RU 95116579 A RU95116579 A RU 95116579A
- Authority
- RU
- Russia
- Prior art keywords
- complex
- antioxidant
- group
- pharmaceutical composition
- alkyls
- Prior art date
Links
- 239000003963 antioxidant agent Substances 0.000 title claims 26
- 239000008194 pharmaceutical composition Substances 0.000 title claims 16
- 239000000203 mixture Substances 0.000 title claims 8
- 201000010099 disease Diseases 0.000 title claims 5
- 210000004962 mammalian cells Anatomy 0.000 title claims 2
- 239000000126 substance Substances 0.000 title claims 2
- 230000002265 prevention Effects 0.000 title 3
- 230000000111 anti-oxidant Effects 0.000 title 1
- 230000003197 catalytic Effects 0.000 title 1
- 239000002516 radical scavenger Substances 0.000 title 1
- 230000003078 antioxidant Effects 0.000 claims 25
- 125000000217 alkyl group Chemical group 0.000 claims 19
- 229910052739 hydrogen Inorganic materials 0.000 claims 10
- 239000001257 hydrogen Substances 0.000 claims 9
- 150000001412 amines Chemical group 0.000 claims 8
- 125000003118 aryl group Chemical group 0.000 claims 7
- 150000001875 compounds Chemical class 0.000 claims 7
- 125000003545 alkoxy group Chemical group 0.000 claims 6
- 150000002431 hydrogen Chemical class 0.000 claims 6
- 229910052736 halogen Inorganic materials 0.000 claims 5
- 150000002367 halogens Chemical class 0.000 claims 5
- 239000002246 antineoplastic agent Substances 0.000 claims 4
- 125000003710 aryl alkyl group Chemical group 0.000 claims 4
- 125000005842 heteroatoms Chemical group 0.000 claims 4
- 125000004104 aryloxy group Chemical group 0.000 claims 3
- 230000015572 biosynthetic process Effects 0.000 claims 3
- -1 fatty acid esters Chemical class 0.000 claims 3
- 238000005755 formation reaction Methods 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 229910052748 manganese Inorganic materials 0.000 claims 3
- 239000011572 manganese Substances 0.000 claims 3
- 210000004369 Blood Anatomy 0.000 claims 2
- 206010061255 Ischaemia Diseases 0.000 claims 2
- 150000001450 anions Chemical class 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 229910052804 chromium Inorganic materials 0.000 claims 2
- 229910052803 cobalt Inorganic materials 0.000 claims 2
- 230000000875 corresponding Effects 0.000 claims 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims 2
- 239000000194 fatty acid Substances 0.000 claims 2
- 230000000642 iatrogenic Effects 0.000 claims 2
- 229910052742 iron Inorganic materials 0.000 claims 2
- 229910052759 nickel Inorganic materials 0.000 claims 2
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 claims 2
- 125000005415 substituted alkoxy group Chemical group 0.000 claims 2
- 230000001629 suppression Effects 0.000 claims 2
- 230000001988 toxicity Effects 0.000 claims 2
- 231100000419 toxicity Toxicity 0.000 claims 2
- 229910052720 vanadium Inorganic materials 0.000 claims 2
- 206010021143 Hypoxia Diseases 0.000 claims 1
- PLRACCBDVIHHLZ-UHFFFAOYSA-N MPTP Chemical compound C1N(C)CCC(C=2C=CC=CC=2)=C1 PLRACCBDVIHHLZ-UHFFFAOYSA-N 0.000 claims 1
- 208000009025 Nervous System Disease Diseases 0.000 claims 1
- 101700060519 PTPN2 Proteins 0.000 claims 1
- 210000003491 Skin Anatomy 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 150000007513 acids Chemical class 0.000 claims 1
- 125000004171 alkoxy aryl group Chemical group 0.000 claims 1
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- 125000002877 alkyl aryl group Chemical group 0.000 claims 1
- 239000002537 cosmetic Substances 0.000 claims 1
- 125000004185 ester group Chemical group 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 230000001146 hypoxic Effects 0.000 claims 1
- 230000003902 lesions Effects 0.000 claims 1
- 239000006210 lotion Substances 0.000 claims 1
- PWHULOQIROXLJO-UHFFFAOYSA-N manganese Chemical group [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 claims 1
- 210000000056 organs Anatomy 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 229910001428 transition metal ion Inorganic materials 0.000 claims 1
Claims (32)
где М выбирают из группы, включающей Мn, Со, Fе, V, Сr, Ni;
А представляет собой анион;
n равно 0, 1 или 2;
X1, Х2, X3 и Х4 независимо выбирают из группы, включающей водород, силилы, арилы, арилалкилы, первичные алкилы, вторичные алкилы, третичные алкилы, алкокси, арилокси, амины, четвертичные амины, гетероатомы и водород;
Y1, Y2, Y3, Y4, Y5, Y6 независимо выбирают из группы, включающей водород, галоиды, алкилы, арилы, арилалкилы, силилы, амины, алкилы или гетероарилы и галоид;
R1, R2, R3, R4 независимо выбирают из группы, включающей водород, арил, сложные эфиры жирных кислот; замещенные алкоксиарилы; ароматические группы, содержащие гетероатом; алкиларилы; первичные алкилы; вторичные алкилы и третичные алкилы.3. The pharmaceutical composition according to claim 1, characterized in that the antioxidant salenmetallic complex has the structural formula
where M is selected from the group including Mn, Co, Fe, V, Cr, Ni;
A represents an anion;
n is 0, 1 or 2;
X 1 , X 2 , X 3, and X 4 are independently selected from the group consisting of hydrogen, silyl, aryl, arylalkyl, primary alkyl, secondary alkyl, tertiary alkyl, alkoxy, aryloxy, amine, quaternary amine, heteroatom, and hydrogen;
Y 1 , Y 2 , Y 3 , Y 4 , Y 5 , Y 6 are independently selected from the group consisting of hydrogen, haloids, alkyls, aryls, arylalkyls, silyls, amines, alkyls or heteroaryls and a halogen;
R 1 , R 2 , R 3 , R 4 are independently selected from the group consisting of hydrogen, aryl, fatty acid esters; substituted alkoxyaryls; aromatic groups containing a heteroatom; alkylaryls; primary alkyls; secondary alkyls and tertiary alkyls.
где М, который является ионом переходного металла, выбирают из группы, включающей Мn, Со, Fе, V, Сr, Ni;
А представляет собой анион;
n равно 4, 5 или 6;
X1, Х2, X3, Х4 независимо выбирают из группы, включающей арилы, арилалкилы, арилокси, первичные алкилы, вторичные алкилы, третичные алкилы, алкокси, замещенную алкокси, гетероатомы, амины, четвертичные амины и водород;
Y1, Y2, Y3, Y4, Y5, Y6 независимо выбирают из группы, включающей в себя арилы, арилалкилы, первичные алкилы, вторичные алкилы, третичные алкилы, алкокси, замещенные алкокси, арилокси, галоиды, гетероатомы, амины, четвертичные амины и водород;
R1, R4 независимо выбирают из группы, включающей водород, галоиды, первичные алкилы, вторичные алкилы, третичные алкилы, сложные эфиры жирных кислот, алкокси или арилы.6. The pharmaceutical composition according to claim 1, characterized in that the antioxidant salenmetallic complex has the structural formula
where M, which is a transition metal ion, is selected from the group consisting of Mn, Co, Fe, V, Cr, Ni;
A represents an anion;
n is 4, 5 or 6;
X 1 , X 2 , X 3 , X 4 are independently selected from the group consisting of aryls, arylalkyls, aryloxy, primary alkyls, secondary alkyls, tertiary alkyls, alkoxy, substituted alkoxy, heteroatoms, amines, quaternary amines and hydrogen;
Y 1 , Y 2 , Y 3 , Y 4 , Y 5 , Y 6 are independently selected from the group consisting of aryls, arylalkyls, primary alkyls, secondary alkyls, tertiary alkyls, alkoxy, substituted alkoxy, aryloxy, halo, heteroatoms, amines quaternary amines and hydrogen;
R 1 , R 4 are independently selected from the group consisting of hydrogen, halogens, primary alkyls, secondary alkyls, tertiary alkyls, fatty acid esters, alkoxy or aryls.
где М представляет собой марганец;
A представляет собой Н или галоген;
n равно 0, 4, 5 или 6, где Сn отсутствует, если n=4, 5 или 6;
R1 и R2 независимо выбирают из группы, включающей Н, фенил, низший алкокси и сложно-эфирную группу низших кислот;
X1 и X3 независимо выбирают из группы, включающей водород, низший алкил, амин, низшую алкиламино-группу и галоген;
Х2 и Х4 представляют собой Н;
Y1 и Y4 независимо выбирают из группы, включающей водород, низший алкил, галоген и низшую алкокси-группу;
Y2, Y3, Y5 и Y6 представляют собой Н; и все остальные положения заместителя заняты Н.29. A pharmaceutical composition comprising a therapeutically effective dose of an antioxidant salenmetal complex in a pharmaceutically acceptable form, wherein said antioxidant salenmetal complex has the following structural formula:
where M is manganese;
A represents H or halogen;
n is 0, 4, 5 or 6, where Cn is absent if n = 4, 5 or 6;
R 1 and R 2 are independently selected from the group consisting of H, phenyl, lower alkoxy, and ester groups of lower acids;
X 1 and X 3 are independently selected from the group consisting of hydrogen, lower alkyl, amine, lower alkylamino group and halogen;
X 2 and X 4 represent H;
Y 1 and Y 4 are independently selected from the group consisting of hydrogen, lower alkyl, halogen, and lower alkoxy;
Y 2 , Y 3 , Y 5, and Y 6 are H; and all other positions of the deputy are occupied by N.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/987,474 US5403834A (en) | 1992-12-07 | 1992-12-07 | Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease |
US07/987,474 | 1992-12-07 | ||
US07/987.474 | 1992-12-07 |
Publications (2)
Publication Number | Publication Date |
---|---|
RU95116579A true RU95116579A (en) | 1998-01-10 |
RU2157213C2 RU2157213C2 (en) | 2000-10-10 |
Family
ID=25533292
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU95116579/14A RU2157213C2 (en) | 1992-12-07 | 1993-12-06 | Pharmaceutical composition and method of prophylaxis, suppression or treatment of disease associated with presence of free radicals |
Country Status (20)
Country | Link |
---|---|
US (2) | US5403834A (en) |
EP (2) | EP1642583A2 (en) |
JP (1) | JP3502099B2 (en) |
KR (1) | KR20040004386A (en) |
AT (1) | ATE290867T1 (en) |
AU (1) | AU697399B2 (en) |
CA (1) | CA2150937C (en) |
CZ (1) | CZ296288B6 (en) |
DE (1) | DE69333775T2 (en) |
GB (2) | GB2277873B (en) |
HU (1) | HU225109B1 (en) |
LV (1) | LV10924B (en) |
NO (1) | NO319454B1 (en) |
NZ (1) | NZ259200A (en) |
OA (1) | OA10165A (en) |
PL (1) | PL175446B1 (en) |
RU (1) | RU2157213C2 (en) |
SK (1) | SK74595A3 (en) |
UA (1) | UA27949C2 (en) |
WO (1) | WO1994013300A1 (en) |
Families Citing this family (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5653685A (en) * | 1990-10-10 | 1997-08-05 | Lrt, Inc. | Method of providing circulation via lung expansion and deflation |
USRE36460E (en) * | 1990-10-10 | 1999-12-21 | Life Science Holdings, Inc. | Method of providing circulation via lung expansion and deflation |
US5834509A (en) * | 1992-12-07 | 1998-11-10 | Eukarion, Inc. | Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease |
US5403834A (en) * | 1992-12-07 | 1995-04-04 | Eukarion, Inc. | Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease |
US5696109A (en) * | 1992-12-07 | 1997-12-09 | Eukarion, Inc. | Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease |
US7582786B2 (en) * | 1992-12-07 | 2009-09-01 | Eukarion Inc. | Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease |
US5686436A (en) * | 1993-05-13 | 1997-11-11 | Hiv Diagnostics, Inc. | Multi-faceted method to repress reproduction of latent viruses in humans and animals |
US6127356A (en) | 1993-10-15 | 2000-10-03 | Duke University | Oxidant scavengers |
US6245758B1 (en) | 1994-05-13 | 2001-06-12 | Michael K. Stern | Methods of use for peroxynitrite decomposition catalysts, pharmaceutical compositions therefor |
PL317192A1 (en) * | 1994-05-13 | 1997-03-17 | Monsanto Co | Methods of using pernitrite decomposition catalyst and their pharmaceutic compositions |
US5681278A (en) * | 1994-06-23 | 1997-10-28 | Cormedics Corp. | Coronary vasculature treatment method |
WO1996004311A1 (en) * | 1994-08-03 | 1996-02-15 | University Of Alabama At Birmingham Research Foundation | Monoclonal antibody to nitrotyrosine, methods for diagnosis and methods for treatment of disease |
US5900433A (en) * | 1995-06-23 | 1999-05-04 | Cormedics Corp. | Vascular treatment method and apparatus |
CA2247876A1 (en) * | 1996-03-08 | 1997-09-12 | Ronald M. Klatz | Liquid ventilation method and apparatus |
AU4258097A (en) | 1996-09-06 | 1998-03-26 | Duke University | Methods for testing compounds for use as therapeutic antioxidants |
US6369106B1 (en) * | 1996-12-26 | 2002-04-09 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Treatment of ischemic brain injuries with brain targeted anti oxidant compounds |
US6214817B1 (en) | 1997-06-20 | 2001-04-10 | Monsanto Company | Substituted pyridino pentaazamacrocyle complexes having superoxide dismutase activity |
US5834178C1 (en) * | 1997-07-09 | 2002-04-23 | Univ Wayne State | Flush-storage solution for donor organs |
US5829449A (en) * | 1997-09-19 | 1998-11-03 | Thione International, Inc. | Smoking products containing antioxidants |
AT409306B (en) * | 1997-10-03 | 2002-07-25 | Hoffmann La Roche | OPTICAL CHEMICAL SENSOR |
WO1999023097A1 (en) | 1997-11-03 | 1999-05-14 | Duke University | Substituted porphyrins |
CA2249778A1 (en) * | 1997-12-15 | 1999-06-15 | Bayer Corporation | Competitive apo-peroxidase assay |
GB9817845D0 (en) | 1998-08-17 | 1998-10-14 | Glaxo Group Ltd | Chemical compounds |
US7816403B2 (en) * | 1998-09-08 | 2010-10-19 | University Of Utah Research Foundation | Method of inhibiting ATF/CREB and cancer cell growth and pharmaceutical compositions for same |
US6703384B2 (en) | 1998-09-23 | 2004-03-09 | Research Development Foundation | Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof |
AU779283B2 (en) | 1999-01-25 | 2005-01-13 | Aeolus Sciences, Inc. | Substituted porphyrins |
US6365385B1 (en) | 1999-03-22 | 2002-04-02 | Duke University | Methods of culturing and encapsulating pancreatic islet cells |
US6303355B1 (en) | 1999-03-22 | 2001-10-16 | Duke University | Method of culturing, cryopreserving and encapsulating pancreatic islet cells |
EP1185312B1 (en) * | 1999-05-27 | 2005-03-23 | Monsanto Company | Biomaterials modified with superoxide dismutase mimics |
US20040110722A1 (en) * | 1999-05-27 | 2004-06-10 | Ornberg Richard L. | Modified hyaluronic acid polymers |
US6179804B1 (en) * | 1999-08-18 | 2001-01-30 | Oxypatch, Llc | Treatment apparatus for wounds |
RU2263672C2 (en) * | 2000-02-11 | 2005-11-10 | Рисерч Дивелопмент Фаундейшн | Tocopherols, tocotrienols, other chromans and derivatives by side chains and their using |
US20040047852A1 (en) * | 2001-03-02 | 2004-03-11 | Kennedy Thomas Preston | Method of treating cancer |
US20030069281A1 (en) * | 2000-06-14 | 2003-04-10 | Irwin Fridovich | Tetrapyrroles |
US6589948B1 (en) | 2000-11-28 | 2003-07-08 | Eukarion, Inc. | Cyclic salen-metal compounds: reactive oxygen species scavengers useful as antioxidants in the treatment and prevention of diseases |
US6481442B1 (en) | 2000-11-28 | 2002-11-19 | Lorillard Licensing Company, Llc | Smoking article including a filter for selectively removing carbonyls |
WO2002043514A1 (en) * | 2000-11-28 | 2002-06-06 | Lorillard Licensing Company, Llc | A smoking article including a selective carbon monoxide pump |
US6692458B2 (en) * | 2000-12-19 | 2004-02-17 | Edwards Lifesciences Corporation | Intra-pericardial drug delivery device with multiple balloons and method for angiogenesis |
AU2002248366B2 (en) * | 2001-01-19 | 2006-10-26 | Aeolus Sciences, Inc. | Cancer therapy |
ITPI20010014A1 (en) * | 2001-03-05 | 2002-09-05 | Ivo Pera | COMPOUND FOR FILTERS FOR CIGARETTES, OR OTHER SMOKING ITEMS, BASED ON ANTIOXIDANT SUBSTANCES AND THE FILTER SO OBTAINED |
KR100681326B1 (en) * | 2001-04-20 | 2007-02-15 | 주식회사 중외제약 | The new manganese-chiral compounds and thereof use |
EP1439842A4 (en) * | 2001-06-01 | 2009-09-02 | Nat Jewish Med & Res Center | Oxidant scavengers for treatment of diabetes or use in transplantation or induction of immune tolerance |
WO2003010153A1 (en) * | 2001-07-26 | 2003-02-06 | Samsung Electronics Co. Ltd. | N-alkyl-n-phenylhydroxylamine compounds containing metal chelating groups, their preparation and their therapeutic uses |
WO2003010154A1 (en) | 2001-07-26 | 2003-02-06 | Samsung Electronics Co. Ltd. | Seleno compounds containing nitrone moiety, their preparation and their therapeutic uses |
WO2003010143A1 (en) | 2001-07-26 | 2003-02-06 | Samsung Electronics Co., Ltd. | Dialkylhydroxybenzoic acid derivatives containing metal chelating groups and their therapeutic uses |
NZ533565A (en) * | 2001-12-19 | 2006-11-30 | Res Dev Foundation | Liposomal delivery of vitamin E based anti-cancer compounds |
US20030236301A1 (en) * | 2001-12-19 | 2003-12-25 | Bob Sanders | Liposomal delivery of vitamin E based compounds |
EP1513537A4 (en) * | 2002-06-07 | 2006-09-06 | Univ Duke | Substituted porphyrins |
US6835387B2 (en) * | 2002-06-11 | 2004-12-28 | Scimed Life Systems, Inc. | Sustained release of superoxide dismutase mimics from implantable or insertable medical devices |
WO2004017959A2 (en) * | 2002-08-22 | 2004-03-04 | University Of Florida | Antioxidant and radical scavenging activity of synthetic analogs of desferrithiocin |
US20040044220A1 (en) * | 2002-08-22 | 2004-03-04 | University Of Florida | Antioxidant and radical scavenging activity of synthetic analogs of desferrithiocin |
RU2361615C2 (en) * | 2002-12-09 | 2009-07-20 | Абраксис Байосайенс, Ллс. | Compositions and ways of pharmacological agents delivery |
HUE040046T2 (en) | 2002-12-09 | 2019-02-28 | Abraxis Bioscience Llc | Compositions and methods of delivery of pharmacological agents |
WO2004052098A1 (en) * | 2002-12-11 | 2004-06-24 | Cryolife, Inc. | Radical retardant cryopreservation solutions |
WO2005030137A2 (en) * | 2003-09-24 | 2005-04-07 | The University Of Toledo, A University Instrumentality Of The State Of Ohio | Improving biomechanical performance of irradiated biological material |
US20050100537A1 (en) * | 2003-11-10 | 2005-05-12 | Evans Gregory S. | Methods and kits for reducing cellular damage, inhibiting free radical production, and scavenging free radicals in mammals |
WO2006078713A2 (en) * | 2005-01-19 | 2006-07-27 | Metaphore Pharmaceuticals, Inc. | Methotrexate combinations for treating inflammatory diseases |
EA010927B1 (en) * | 2005-05-04 | 2008-12-30 | Коти Престиж Ланкастер Груп Гмбх | The use of free radical scavengers for protecting and treating skin and hair damages caused by chemotherapy |
EP2036550A4 (en) * | 2006-06-28 | 2009-07-15 | Ihi Corp | Drug, drug induction device, magnetic detector and method of designing drug |
WO2008070557A2 (en) * | 2006-12-01 | 2008-06-12 | Women & Infants Hospital | Organometallic complexes as therapeutic agents |
US20090169484A1 (en) | 2007-12-28 | 2009-07-02 | Ihi Corporation | Iron-salen complex |
US11382895B2 (en) | 2008-05-23 | 2022-07-12 | National Jewish Health | Methods for treating injury associated with exposure to an alkylating species |
WO2010058280A1 (en) * | 2008-11-20 | 2010-05-27 | 株式会社Ihi | Auto magnetic metal salen complex compound |
KR101050273B1 (en) * | 2008-11-21 | 2011-07-19 | 세종대학교산학협력단 | Salen transition metal complex, and preparation method thereof |
CN102834512A (en) * | 2010-04-06 | 2012-12-19 | 株式会社Ihi | Metal salen complex derivative and process for production thereof |
WO2011135784A1 (en) * | 2010-04-28 | 2011-11-03 | 株式会社Ihi | Anti-brain-tumor drug |
EP2578643B1 (en) * | 2010-06-01 | 2019-07-10 | IHI Corporation | Fluorescent dye material and use thereof |
RU2546663C2 (en) * | 2010-12-21 | 2015-04-10 | АйЭйчАй КОРПОРЕЙШН | Complex metal-salen compound and method of obtaining thereof |
JP5873656B2 (en) | 2011-06-13 | 2016-03-01 | 株式会社Ihi | Metal salen complex compounds, local anesthetics and antineoplastic agents |
JP6017766B2 (en) * | 2011-07-26 | 2016-11-02 | 株式会社Ihi | Novel anticancer agent of metal salen complex compound |
CN104010660A (en) | 2011-10-04 | 2014-08-27 | 株式会社Ihi | Medicinal agent responsive to metal salen complex compound, and system for controlling in vivo behavior of metal salen complex compound |
JP6046338B2 (en) * | 2011-10-27 | 2016-12-14 | 株式会社Ihi | Radical inhibitor |
MX2014008247A (en) | 2012-01-05 | 2015-03-09 | Pledpharma Ab | Calmangafodipir, a new chemical entity, and other mixed metal complexes, methods of preparation, compositions, and methods of treatment. |
CN108030926B (en) * | 2017-12-15 | 2021-07-13 | 武汉工程大学 | Salen-type manganese complex-chitosan composite material with high SOD enzyme activity and preparation method thereof |
RU2699040C1 (en) * | 2018-07-23 | 2019-09-03 | Федеральное государственное бюджетное учреждение науки "Уральский научно-практический центр радиационной медицины Федерального медико-биологического агентства" (ФГБУН УНПЦ РМ ФМБА России) | Method for emergency prevention and treatment of acute radiation sickness (versions) |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4540573A (en) * | 1983-07-14 | 1985-09-10 | New York Blood Center, Inc. | Undenatured virus-free biologically active protein derivatives |
US5106841A (en) * | 1986-05-13 | 1992-04-21 | Chai-Tech Corporation | Antiviral compositions and method for their use |
US5223538A (en) * | 1987-03-31 | 1993-06-29 | Duke University | Superoxide dismutase mimic |
WO1993003838A1 (en) * | 1991-08-26 | 1993-03-04 | Research Corporation Technologies, Inc. | Chiral catalysts, catalytic oxidation and disproportionation reactions, and methods of producing epoxychromans and taxol |
US5403834A (en) * | 1992-12-07 | 1995-04-04 | Eukarion, Inc. | Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease |
-
1992
- 1992-12-07 US US07/987,474 patent/US5403834A/en not_active Expired - Lifetime
-
1993
- 1993-12-06 EP EP05005538A patent/EP1642583A2/en not_active Withdrawn
- 1993-12-06 GB GB9415050A patent/GB2277873B/en not_active Expired - Fee Related
- 1993-12-06 GB GB9621087A patent/GB2305107B/en not_active Expired - Fee Related
- 1993-12-06 RU RU95116579/14A patent/RU2157213C2/en not_active IP Right Cessation
- 1993-12-06 KR KR10-2003-7004595A patent/KR20040004386A/en not_active Application Discontinuation
- 1993-12-06 JP JP51432894A patent/JP3502099B2/en not_active Expired - Fee Related
- 1993-12-06 AU AU57419/94A patent/AU697399B2/en not_active Ceased
- 1993-12-06 PL PL93309334A patent/PL175446B1/en not_active IP Right Cessation
- 1993-12-06 EP EP94903498A patent/EP0746321B1/en not_active Expired - Lifetime
- 1993-12-06 HU HU9501644A patent/HU225109B1/en not_active IP Right Cessation
- 1993-12-06 NZ NZ259200A patent/NZ259200A/en not_active IP Right Cessation
- 1993-12-06 UA UA95062707A patent/UA27949C2/en unknown
- 1993-12-06 DE DE69333775T patent/DE69333775T2/en not_active Expired - Lifetime
- 1993-12-06 CZ CZ0144295A patent/CZ296288B6/en not_active IP Right Cessation
- 1993-12-06 CA CA002150937A patent/CA2150937C/en not_active Expired - Fee Related
- 1993-12-06 WO PCT/US1993/011857 patent/WO1994013300A1/en active IP Right Grant
- 1993-12-06 SK SK745-95A patent/SK74595A3/en unknown
- 1993-12-06 AT AT94903498T patent/ATE290867T1/en not_active IP Right Cessation
-
1995
- 1995-01-26 US US08/380,731 patent/US5827880A/en not_active Expired - Lifetime
- 1995-06-06 NO NO19952237A patent/NO319454B1/en not_active Application Discontinuation
- 1995-06-06 OA OA60674A patent/OA10165A/en unknown
- 1995-06-06 LV LVP-95-158A patent/LV10924B/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU95116579A (en) | PHARMACEUTICAL COMPOSITION (VARIANTS) AND A METHOD FOR PREVENTION OR TREATMENT (VARIANTS) COMPOSITION FOR PREVENTION OF RADIATION AND CHEMICAL, mammalian cells SYNTHETIC CATALYTIC radical scavengers USED AS ANTIOXIDANTS FOR PREVENTION AND TREATMENT OF DISEASES | |
CA1334170C (en) | Methods of treating tumors with compositions of catecholic butanes | |
CA1226220A (en) | Preparation and method for the treatment of acne | |
KR920700200A (en) | 19-nor-vitamin D compound | |
DE2827018A1 (en) | ANTI-INFLAMMATORY, ANALGETIC, GELLED Ointment | |
DE3832218A1 (en) | Compositions for Topical Application with Melanin Synthesis Inhibitory Activity | |
WO1988003026A1 (en) | Compositions of catecholic butanes with zinc | |
IE50549B1 (en) | Pharmaceutical compositions containing a corticosteroid substance | |
Cowger et al. | Relation of barbiturate structure to DPNH oxidase inhibition | |
US5760037A (en) | Derivatives of N'N'-di(aralkyl)-N,N'-di(2-azaaralkyl)alkylene diamine and the use thereof in pharmaceutical and cosmetic compostions | |
ATE178608T1 (en) | METAL-ORGANIC COBALT COMPOUNDS AND THEIR USES | |
DE60033383T2 (en) | USE OF TETRAHYDROCURCUMINOIDS FOR THE REGULATION OF PHYSIOLOGICAL AND PATHOLOGICAL CASES IN THE SKIN AND MUCOSA | |
DE69728536T2 (en) | Preparations containing a nitrone compound for use in the treatment of uveitis | |
US6482855B2 (en) | Diamine alkylene diacetic or triacetic acid derivatives, preparation method, use in cosmetic and pharmaceutical compositions and compositions containing them | |
US4520132A (en) | Use of undecylenic acid to treat herpes labialis | |
CN108778263A (en) | Stabilizing pharmaceutical composition and application thereof for local application | |
KR960700711A (en) | Medicine for treating or preventing cerebrovascular diseases | |
US4720379A (en) | Use of dimercaptopropanesulfonic acid and dimercapto-propanesuccinic acid for the preparation of pharmaceutical compositions and a method of treatment | |
JPH03170422A (en) | Treatment of skin disease | |
DE1922192C2 (en) | Compositions for the treatment of trophic disorders of the skin and processes for their preparation | |
DE2755198A1 (en) | DIHYDROXYBENZOESAEE DERIVATIVES AND THE SAME-CONTAINING PAIN AND INFLAMMATORY AGENT | |
USRE32990E (en) | Use of undercylenic acid to treat herpes labialis | |
AT394946B (en) | METHOD FOR TREATING PIGS IN PIGS DYSENTERIA CAUSED BY PRIMAER BY TREPONEMA HYODYSENTERIAE | |
JPH0774190B2 (en) | N, N-bis (4-fluorophenyl) carbamoylacetohydroxamic acid and excitatory antidepressant containing the same | |
TSEGA | Long-term effect of high-dose, short-course chloroquine therapy on porphyria cutanea tarda |